ライフサイエンスコーパス: IGF receptor

1 significant numbers of cells expressing the IGF receptor.

2 mediated through interaction with the type 1 IGF receptor.

3 nity similar to that of IGF-I for the type I IGF receptor.

4 n NIH 3T3 cells over-expressing human type-I IGF receptor.

5 rving reductions in transmission mediated by IGF receptors.

6 tive and engineered ligands activate insulin-IGF receptors.

7 , which control their access to cell-surface IGF receptors.

8 hich allows IGF-I to better equilibrate with IGF receptors.

9 Therapeutic targeting of the IGFBP2/IGF receptor 1 signaling axis using small molecules and

10 n experiments revealed galectin-3 binding to IGF-receptor 1 (R1), thus suggesting that interaction of

11 s to IGF-2 (18% cell death), antibody to the IGF receptor (45% cell death), and IGF-1 antisense oligo

12 ve studied the mechanism by which endogenous IGF receptors activate the ERK1/2 mitogen-activated prot

13 Bioactive IGF was assessed by cell-based IGF receptor activation assay.

14 h insulin receptor activation increasing and IGF receptor activation decreasing NAc excitatory transm

15 availability and, hence, local regulation of IGF receptor activation.

16 yperglycemia is not because of altered IGF-1/IGF receptor activation.

17 ated the immune checkpoint CD274 (PD-L1) via IGF receptor/AKT/ERK-dependent signalling.

18 I exhibits 2-fold increased affinity for the IGF receptor and augmented post-receptor signaling.

19 ls resulted in enhanced activation of type I IGF receptor and IRS adaptor proteins.

20 is rapidly internalized after binding to the IGF receptor and is rapidly catabolized with release of

21 fibroblasts also accumulate acidic vesicles, IGF receptor and transferrin, indicating that dysferlin

22 on is mediated by high affinity cell surface IGF receptors and modulated by a family of secreted IGF

23 long-lived daf-2/insulin like growth factor (IGF) receptor and short lived daf-16/FOXO transcription

24 RS), insulin and insulin-like growth factor (IGF) receptors and polypeptides, Notch, Jagged, and HES

25 nd IGF-2, an antibody that blocks the type 1 IGF receptor, and antisense oligonucleotides to inhibit

26 he actions of IGF-I at a point distal to the IGF receptor, and this was not due to IL-1beta-induced c

27 GFs from degradation, limit their binding to IGF receptors, and modulate IGF actions.

28 onal insights into the activation of insulin-IGF receptors, and summarize new agonists and antagonist

29 apoptosis, suggesting that neither IGFs nor IGF receptors are required for this action.

30 ion system inhibited DNA synthesis in an IGF-IGF receptor axis-independent fashion and resulted in th

31 t cancer cell growth, independent of the IGF-IGF receptor axis.

32 anti-IGF-II, anti-insulin receptor, or anti-IGF receptor blocking antibodies caused a significant de

33 t monkeys in the presence and absence of the IGF receptor blocking antibody and ceramide to induce ce

34 A secreted dominant-negative type I IGF receptor (DN-IGFR) had the opposite effect.

35 ossesses two functional copies of the Type-1 IGF receptor gene (igf1ra, igf1rb).

36 2 gene, or conditional disruption of the two IGF receptor genes Igf1r and Insr together in the myocar

37 The insulin/IGF receptor homolog DAF-2 regulates the aging in C. ele

38 mRNA levels for IGF-II, IGF receptor-I, GRP receptor, and EGF receptor in tumors

39 ndent tyrosine phosphorylation of the type I IGF receptor (IGF-IR) and extracellular signal-regulated

40 rated that SHPS-1 was a substrate for type I IGF receptor (IGF-IR) and that IRS-1 competitively inhib

41 ast cancer cells to inhibitors of the type I IGF receptor (IGF-IR) in a manner reversed by the reacti

42 (IGF-I) to induce phosphorylation of type I IGF receptor (IGF-IR), insulin receptor substrate 1, pho

43 ced SH-SY5Y growth is mediated by the type I IGF receptor (IGF-IR).

44 1, including enhanced phosphorylation of the IGF receptor (IGF-R) and insulin receptor substrate as w

45 cer cell lines through action via the type I IGF receptor (IGF-R).

46 cDNAs were more similar to the human type I IGF receptor (IGF-R).

47 The insulin-like growth factor (IGF) receptor (IGF-IR) is necessary for IGF signalling a

48 Signaling through IGF receptor (IGF1R) activated the protein kinase B-mamm

49 ts of the malignant phenotype via the type I IGF receptor (IGF1R) and insulin receptor (IR).

50 Insulin receptor (IR) and the type I IGF receptor (IGF1R) are structurally and functionally r

51 Inhibition of IGF receptor (IGF1R) delays repair of radiation-induced

52 ment to evaluate the potential of the type 1 IGF receptor (Igf1r) for targeted anticancer therapy in

53 (IGF-I and IGF-II) and their cognate type 1 IGF receptor (IGF1R) have demonstrated that this signali

54 lonal antibodies directed against the type I IGF receptor (IGF1R) in combination with estrogen recept

55 iferation, motility, and survival.The type I IGF receptor (IGF1R) mediates the effects of IGF-I.

56 Expression of type-1 IGF receptor (IGF1R) mRNA, encoding the cognate receptor

57 fectively antagonizes PAPP-A-mediated type 1 IGF receptor (IGF1R) phosphorylation.

58 king GPC3 and also IGF2, IGF1, or the type 1 IGF receptor (IGF1R) provided conclusive genetic evidenc

59 ific conditional mutagenesis ablating type 1 IGF receptor (IGF1R) signaling.

60 s by disrupting the gene encoding the type 1 IGF receptor (IGF1R) specifically in the mouse brain by

61 hile IGF signaling is mediated by the type 1 IGF receptor (IGF1R), the type 2 receptor (IGF2R/CI-MPR)

62 use osteoblasts the gene encoding the type 1 IGF receptor (Igf1r).

63 le of the type I insulin-like growth factor (IGF) receptor (IGF1R) in cancer metastasis we inhibited

64 oding the type 1 insulin-like growth factor (IGF) receptor (IGF1R).

65 for both IGF-I and IGF-II, as well as type-2 IGF receptor (IGF2R) mRNA was not found to be altered du

66 GF-II-binding function and is termed type II IGF receptor (IGF2R).

67 In this study, we examined the role of the IGF receptor (IGFR) and the importance of IGFR glycosyla

68 (IGF) is a potent mitogen that activates the IGF receptor (IGFR)/insulin receptor substrate (IRS) axi

69 ty to the type 1 insulin-like growth factor (IGF) receptor (IGFR).

70 hat neutralization of IGF action by a type I IGF receptor (IGFR1) blocking antibody or neutralization

71 signaling pathways downstream of the type I IGF receptor in a subset of malignant pleural mesothelio

72 lts in dose-dependent phosphorylation of the IGF receptor in the range of 1 to 100 nM.

73 lower amount of IGF that is able to bind to IGF receptors in the arthritic joint.

74 itated the autophosphorylation of the type 1 IGF receptor, increased class IA phosphatidylinositol 3'

75 that this action is mediated through an IGF.IGF receptor-independent pathway.

76 Importantly, the IGF receptor inhibitor NVP-AEW541 and the neutralization

77 Insulin-IGF receptor (InR) signaling has a conserved role in reg

78 daf-2, an insulin/insulinlike growth factor (IGF) receptor (INR) homolog gene, were profoundly Hyp.

79 amed kermit 2 (also recently described as an IGF receptor interacting protein and named XGIPC).

80 results demonstrate that IGF-1 activates the IGF receptor/IRS/PI3K/PKB pathway, and that PI3Kalpha is

81 Phosphorylation of the IGF receptor is rapid and sustained, with maximal phosph

82 .3-3.9 nM) and no biological activity at the IGF receptors (Ki = >10,000 nM) increased the levels of

83 To determine which IGF receptors mediate this effect, we tested seven insul

84 pathway independent of either p53 or the IGF.IGF receptor-mediated cell survival pathway and that IGF

85 r (IGFR) and is essential for activating the IGF receptor-mediated intracellular signalling pathway.

86 Type-2 IGF receptor mRNA expression was reduced to background l

87 ected insulin, IGF-II, insulin receptor, and IGF receptor mRNAs in both the neural tube and the somit

88 daf-2 insulin/IGF receptor mutants have a constitutive-L1-arrest pheno

89 In addition, in an IGF receptor-negative mouse fibroblast cell line, treatm

90 bound IGFBP-3 allows IGF-I release to type I IGF receptors of stromal cells migrating into the fibrin

91 e growth factor (IGF) pathway and the type I IGF receptor on Purkinje cells.

92 actors (IGF) 1 and 2, which activate insulin/IGF receptors on pancreatic cancer cells.

93 of the patients expressed activated insulin/IGF receptors on tumor cells, and this positively correl

94 of insulin-like signaling via DAF-2 insulin/IGF receptor or its intramuscular effector PtdIns-3-kina

95 rent from those resulting from deficiency of Igf receptor or ligand in zebrafish, suggesting a functi

96 Age-related changes in IGF receptors or, more likely, age-related alterations i

97 id not change the expression levels of IGFs, IGF receptors, or other IGFBPs.

98 e to nutrition, and we show that the insulin/IGF receptor pathway is necessary for neuroblasts to exi

99 el with the glp-1 (Notch) and daf-2 (insulin-IGF receptor) pathways, and does not share the same gene

100 ing the survival effect of IGF-I we examined IGF receptor phosphorylation and Akt phosphorylation and

101 IGF-1 secretion and IGF receptor phosphorylation by autocrine IGF-1 occur eq

102 The IGF pathway, acting through the type 1 IGF-receptor, repressed apoptosis of lung fibroblasts bu

103 of DOG1 in GIST involving modulation of IGF/IGF receptor signaling in the tumor microenvironment thr

104 at STC2 efficiently inhibits PAPP-A-mediated IGF receptor signaling in vitro and that transgenic mice

105 BP5) expression, which consequently dampened IGF receptor signaling.

106 rease IGF bioavailability, thereby enhancing IGF receptor signaling.

107 This translocation is a type 1 IGF receptor-signaling independent event as IGFBP-3 indu

108 to regulating metabolism and growth, insulin-IGF receptor signalling has recently been linked to a va

109 ceptor interactions and functions of insulin-IGF receptor signalling in diseases.

110 affect receptor activation, and how insulin-IGF receptor signalling translates into pleiotropic biol

111 for intervening in the activation of insulin-IGF receptor signalling.

112 cluding Irs1 and Irs2, integrate insulin and IGF receptor signals with heterologous pathways to coord

113 ibody (alphaIR3) directed against the type 1 IGF receptor significantly attenuated the ability of IGF

114 ncer cells by a mechanism that relies on the IGF receptor substrate-1 (IRS-1).

115 f2r gene on chromsome 17 encoding the type 2 IGF receptor that is involved in degradation of excess I

116 r and for targeting of insulin receptors and IGF receptors to alter motivation.

117 ect of antisense insulin-like growth factor (IGF) receptor transcripts on the proliferation and tumor

118 factor in several tumor types by binding to IGF receptor type 1 (IGF-1R) and/or the insulin receptor

119 .05) decrease in insulin-like growth factor (IGF) receptor type I beta and an approximately 13-fold (

120 Cell death from inhibition of the type 1 IGF receptor was associated with an increase in caspase

121 were those from young adult monkeys when the IGF receptor was blocked and cell death was further stim

122 afficking of the insulin-like growth factor (IGF) receptor, where the receptor is shuttled to LAMP2-p